Wei Zhang, Jingjing Wang, Long Ngo, Li Li, Yuling Wang
{"title":"Recent Advances in Cancer Cell Membrane-Based Nanoparticles and Cancer Cell-Derived Small Extracellular Vesicles as Drug Delivery Platforms","authors":"Wei Zhang, Jingjing Wang, Long Ngo, Li Li, Yuling Wang","doi":"10.1002/anbr.202500008","DOIUrl":null,"url":null,"abstract":"<p>Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment. Cancer cell membrane-based nanoparticles (CCM-NPs) and cancer cell-derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for cancer treatment due to their inherent properties such as low immunogenicity and natural targeting capabilities to cancer cells. However, a comprehensive comparison of the advantages, disadvantages, and similarities of these two platforms is lacking. This review summarizes the natural, engineered, and hybrid forms of CCM-NPs and CsEVs-based drug delivery platforms with a focus on comparison of these two platforms, considering key aspects including preparation methods, drug encapsulation strategies, delivery pathways, immune evasion, targeting ability, and their potential for clinical applications. By understanding the strengths and weaknesses of each approach, the aim is to pave the way for next-generation nanoscale drug delivery platforms and contribute to the development of more effective and personalized cancer therapies.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 6","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202500008","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202500008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment. Cancer cell membrane-based nanoparticles (CCM-NPs) and cancer cell-derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for cancer treatment due to their inherent properties such as low immunogenicity and natural targeting capabilities to cancer cells. However, a comprehensive comparison of the advantages, disadvantages, and similarities of these two platforms is lacking. This review summarizes the natural, engineered, and hybrid forms of CCM-NPs and CsEVs-based drug delivery platforms with a focus on comparison of these two platforms, considering key aspects including preparation methods, drug encapsulation strategies, delivery pathways, immune evasion, targeting ability, and their potential for clinical applications. By understanding the strengths and weaknesses of each approach, the aim is to pave the way for next-generation nanoscale drug delivery platforms and contribute to the development of more effective and personalized cancer therapies.
期刊介绍：
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
